Genomic opportunities for drug repositioning in systemic seropositive rheumatic diseases

Figures & data

Figure 1. Principal computational (blue boxes) and experimental (green boxes) strategies used in drug repositioning. *GWAS: Genome-Wide Association Studies; PheWAS: Phenome-Wide Association Studies.

Table 1. Main drugs proposed for repositioning in systemic seropositive rheumatic diseases.

Disease	Associated genes	Proposed drug for repositioning*	Current indication for the drug	Reference
RA	CDK4, CDK6	Palbociclib	Breastcancer, lymphoma	[13]
RA	CDK4, CDK6	Capridine-beta	Solid tumors, psoriaticaffections	[13]
RA	CDK4, CDK6	Flavopiridol	Leukemia, lymphoma, carcinoma	[13]
IIM, SLE, SSc	IL12A, TYK2	Tocilizumab	RA	[16]
IIM, SLE, SSc	PTPN2, STAT4	Tofacitinib	RA	[16]
SSc	TNFAIP3	Etanercept	RA	[16]
IIM, SLE, SSc	IL12RB2	Canakinumab, anakinra, tofacitinib	RA	[16]
IIM, SSc	GLS	Azathioprine	RA, SLE	[16]
RA, SLE, SSc, IIM	DGKQ	Orlistat	Obesity	[16]
IIM, RA, SLE	FAM167A-BLK	Nintedanib	SSc	[16]

*Based on the shared genetics among diseases.

In boldface the drugs proposed in more than one study.

Okada Y, Wu D, Trynka G, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014 Feb 20;506(7488):376–381.

 PubMed Web of Science ®Google Scholar

Acosta-Herrera M, Lopez-Isac E, Martin J. Towards a better classification and novel therapies based on the genetics of systemic sclerosis. Curr Rheumatol Rep. 2019 Jul 15;21(9):44.

 PubMed Web of Science ®Google Scholar